RNA Interference
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis
Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development
Arrowhead Pharmaceuticals, cardiometabolic drug, plozasiran, zodasiran, RNAi therapies, cardiovascular disease, triglycerides, LDL cholesterol
Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran
Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy
Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial
Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile
Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet
Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study